# Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.

> **NCT04877496** · — · UNKNOWN · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 425 (estimated)

## Conditions studied

- COVID19 Vaccination
- Rituximab
- Immunosuppression

## Interventions

- **DRUG:** History of exposure to anti-CD20 treatment since 01/01/2010
- **BIOLOGICAL:** Completion of COVID19 vaccine at least 4 weeks ago

## Key facts

- **NCT ID:** NCT04877496
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-26
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-10-31
- **Target enrollment:** 425 (ESTIMATED)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877496, "Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04877496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*